A worldwide look into long COVID-19 management: an END-COVID survey.

Autor:	Nigro M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy., Valenzuela C; Pulmonology Department, Hospital Universitario de La Princesa, Universidad Autonoma de Madrid, Madrid, Spain., Arancibia F; Pulmonology Department, Instituto Nacional del Tórax, Universidad de Chile, Santiago, Chile., Cohen M; Pulmonary and Critical Care, Hospital Centro Médico, Guatemala., Lam DCL; Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong SAR, China., Maves RC; Sections of Infectious Diseases and Critical Care Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Rath B; Vaccine Safety Initiative, Div. Infectious Diseases, Berlin, Germany., Simpson SQ; Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Song Y; Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Respiratory Research Institute, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China., Tsiodras S; National and Kapodistrian University of Athens, Athens, Greece.; University Hospital of Athens Attikon, Athens, Greece., Chalmers JD; Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK., Aliberti S; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2024 Nov 11; Vol. 10 (6). Date of Electronic Publication: 2024 Nov 11 (Print Publication: 2024).
DOI:	10.1183/23120541.00096-2024
Abstrakt:	Background: Long COVID is a heterogeneous clinical syndrome characterised by a variety of reported symptoms and signs. Its clinical management is expected to differ significantly worldwide. Methods: A survey-based study investigating long COVID-related standard operating procedures (SOPs) has been conducted by the European Respiratory Society (ERS) END-COVID clinical research collaboration with the support of other international societies (ALAT, APSR, CHEST, ESCMID and PATS). A global analysis of the results is provided here, alongside sub-population analysis based on continents, national income levels, type of involved healthcare professional and inclusion or exclusion of paediatric patients. Findings: 1015 healthcare professionals from 110 different countries worldwide participated in this study, the majority of them being respiratory physicians (60.6%). A dedicated long COVID programme was present in 55.4% of the investigated institutions, with hospital admission during the acute infection being the main inclusion criteria to access them. Consistent differences in long COVID-related procedures were identified among centres, mainly regarding the multidisciplinary approach, the availability of telemedicine and psychological support, the type of requested exams and the total amount of visits in the centre. Interpretation: Long COVID management shows important differences related to geographical areas and national income levels. SOPs were significantly different when centres were managed by a pulmonologist or when paediatric patients were included. Competing Interests: Conflict of interest: M. Nigro has nothing to disclose. Conflict of interest: C. Valenzuela reports consulting fees from Boehringer Ingelheim, Hoffman-La Roche Ltd and BMS, and payment of honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events and support for attending meetings and/or travel from Boehringer Ingelheim, in the past 36 months. Conflict of interest: F. Arancibia has nothing to disclose. Conflict of interest: M. Cohen is past president of ALAT. Conflict of interest: D.C.L. Lam is president of the APSR and FIRS. Conflict of interest: R.C. Maves reports clinical trial funding to his institution from AiCuris, Sound Pharmaceuticals and GeoVax; travel funding provided for committee work as a member of the American College of Chest Physicians (CHEST) Scientific Program Committee from CHEST, the Society of Critical Care Medicine (SCCM) Scientific Program Committee from the SCCM and the American Board of Internal Medicine (ABIM) Critical Care Medicine Approval Committee from the ABIM; honoraria paid to himself for clinical trial support as a medical monitor and data safety monitoring board member from LumaBridge, and for scientific advisory panel membership from Shionogi, all in the past 36 months; and a US patent on the candidate dengue vaccine unrelated to this study; and is chair of the CHEST Disaster Response and Global Health Section, and the CHEST Rapid Response Task Force, and a member of the CHEST Scientific Program Committee (all unpaid except for official travel funding as above); chair of the SCCM FCCS Crisis Management Committee, a member of the SCCM Congress Program Committee, Co-Vice Chair of the SCCM 2025 Critical Care Congress and Designated Co-Chair of the SCCM 2026 Critical Care Congress (all unpaid except for official travel funding as above); and a member of the ABIM Critical Care Medicine Approval Committee (travel funded plus honorarium for Board service). Conflict of interest: B. Rath reports European Union funding only; support for attending meetings and/or travel for MedScape and scientific societies only; patents not pertinent to this article; participation on a data safety monitoring or advisory board for GSK COVID-19 and influenza infant clinical trials, all in the past 36 months; and is on ISIRV, ESGREV, AAP and IPA vaccination-related steering committees. Conflict of interest: S.Q. Simpson is a board member of the American College of Chest Physicians and Chair of the Board of Directors of the Sepsis Alliance. Conflict of interest: Y. Song is a board member of the American College of Chest Physicians and Chair of the Board of Directors of the Sepsis Alliance. Conflict of interest: S. Tsiodras reports grants or contracts for the European Union (EU) projects EU-RESPONSE (funded by EU Horizon 2020), EU Prevent and EU Reverse, paid to his institution in the past 36 months. Conflict of interest: J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, Gilead Sciences, Grifols, Genentech, GlaxoSmithKline, Insmed and Novartis; and consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Gilead Sciences, Grifols, Genentech, GlaxoSmithKline, Insmed, Novartis, Roche, Trudell, Zambon, Janssen and Pfizer, all in the past 36 months; and is an associate editor of this journal. Conflict of interest: S. Aliberti reports grants or contracts from Insmed Inc., Chiesi, Fisher and Paykel and GSK, paid to his institution; royalties or licences from McGraw Hill, paid to himself; consulting fees from Insmed Inc., Insmed Italy, Insmed Ireland Ltd, Zambon Spa, AstraZeneca UK Ltd, AstraZeneca Pharmaceutical LP, CSL Behring GmbH, Grifols, Fondazione Internazionale Menarini, Moderna, Chiesi, MSD Italia S.r.l., Brahms, Physioassist SAS and GlaxoSmithKline Spa, paid to himself; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GlaxoSmithKline Spa, ThermoFisher Scientific, Insmed Italy, Insmed Ireland Ltd, Zambon and Fondazione Internazionale Menarini; and participation on a data safety monitoring or advisory board from Insmed Inc., Insmed Italy, AstraZeneca UK Ltd and MSD Italia S.r.l., all in the past 36 months. (Copyright ©The authors 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu